Using plasma proteomics to understand Alzheimer’s and other brain diseases
Using plasma proteomics to understand Alzheimer’s and other brain diseases
The plasma proteome presents a goldmine of information that can be used to develop diagnostic tests and identify novel drug targets. In this webinar, our expert speaker Dr. Keenan Walker describes his research into understanding the proteins, protein networks and biological pathways involved in age-related neurodegenerative diseases and vascular cognitive impairment.
Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebrospinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.
Learn about:
- Proteins most strongly implicated in dementia risk
- How combining proteomics with neuroimaging to provide new insights into cerebral small vessel disease
- The process of nominating potentially casual proteins and genetically validating biomarkers
Keenan Walker, PhD
Chief, Multimodal Imaging of Neurodegenerative Disease (MIND)
National Institute on Aging
Keenan Walker, PhD, is an investigator at the National Institute on Aging Intramural Research Program and Chief of the Multimodal Imaging of Neurodegenerative Disease (MIND) unit. Dr. Walker’s current research program focuses on understanding the role of abnormal immune function in Alzheimer’s disease and late-life cognitive decline.
Using plasma proteomics to understand Alzheimer’s and other brain diseases
A presentation by Keenan Walker, PhD
More webinars
WebinarBoutique Webinar: Multiomic Breakthroughs: Immune Monitoring for Precision Disease Detection
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.